
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx Inc has demonstrated significant growth in its operational capacity, achieving a total of 240 active implanting centers at the end of the quarter, which reflects an increase of 13 centers sequentially. Although the company's total operating expenses rose approximately 8% year-over-year to $25.8 million, this increase is mainly attributed to a notable 11% year-over-year hike in selling, general, and administrative costs to $23.4 million. The ongoing expansion of implanting centers, coupled with the innovative Barostim platform technology, positions CVRx favorably in the growing market for minimally invasive neuromodulation solutions for cardiovascular diseases.
Bears say
CVRx Inc has revised its FY25 revenue guidance downward to a range of $55.0 - $57.0 million, indicating a limited growth forecast of approximately 7-11% year-over-year. Additionally, the company has reduced its 2026 revenue estimate from $74.1 million to $67.6 million, suggesting a slower-than-expected ramp in U.S. market performance. The gross margin remained flat at 84% in 2Q25, which raises concerns about the company’s ability to enhance profitability amidst declining revenue projections.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares